Wright Medical Group N.V. Announces Termination of Contingent Value Rights Agreement
AMSTERDAM, The Netherlands, March 11, 2019 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced the expiration in accordance with its terms of the Contingent Value Rights Agreement dated as of March 1, 2013 between Wright Medical Group, Inc. and American Stock Transfer & Trust Company, LLC (CVR Agreement). Accordingly, the CVR Agreement, which was entered into in connection with Wright’s acquisition of BioMimetic Therapeutics, Inc., is terminated effective March 1, 2019. The Contingent Value Rights traded on the NASDAQ under the symbol WMGIZ.
About Wright Medical Group N.V.
Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. For more information about Wright, visit www.wright.com.
™ and ® denote trademarks and registered trademarks of Wright Medical Group N.V. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investors & Media:
Julie D. Dewey
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
Upcoming Life Sciences Events
- June 2019
- London: The Pharma Business Development Course
- Lille: MedFIT
- Cambridge: Health Horizons Future Healthcare Forum